Title: Fungaemia at a tertiary-care hospital: species distribution, antifungal susceptibility and antifungal therapy
Authors: Lagrou, Katrien ×
Verhaegen, Jan
Peetermans, Willy
De Rijdt, Thomas
Maertens, Johan
Van Wijngaerden, Eric #
Issue Date: Apr-2006
Publisher: Blackwell Synergy
Host Document: Clinical microbiology and infection vol:vol. 12 issue:s4 pages:1-1
Conference: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) edition:16 location:Nice date:April 1-4th 2006
Abstract: Objectives: Few data are available regarding the susceptibility of Belgian yeast isolates to commonly used antifungal agents. Both species identification and antifungal susceptibility data are routinely used to guide antimicrobial therapy in episodes of candidemia. The aim of this study was to determine the susceptibility to seven antifungal agents for all yeasts isolated from blood cultures during a one year period and to review the species distribution and the antifungal therapy given.
Methods: From June 2004 until June 2005, the first yeast isolate from each fungemic episode was collected and stored at –70 C. Susceptibility testing was performed using Sensititre YeastOne plate according to the instructions of the manufacturer. Antifungal drugs tested were fluconazole (FZ), amphotericin B (AB), voriconazole (VZ), caspofungin (CA), flucytosine (FC), ketoconazole (KZ) and itraconazole (IZ). Antifungal usage data for each patient with fungemia were obtained from the Hospital Pharmacy.
Results: A total of 62 isolates from 60 patients were collected. 33% of the isolates were non-albicans species (11 Candida glabrata, 5 Candida parapsilosis, 1 Candida krusei, 1 Candida lusitaniae, 1 Candida tropicalis and 1 Saccharomyces cerevisiae). The susceptibility results (MIC range; MIC90s (mg/L)) for all isolates tested were as follows: FZ (<0.008–64; 16), AB (<0.008–1;1), VZ (<0.008–1; 0.25), CA (<0.008–0.5; 0.12), FC (<0.03–4; 0.12), KZ (<0.008–16; 0.5) and IZ (<0.008–>16; 1). All C. albicans isolates were fully susceptible to FZ. 91% of the C. glabrata isolates showed decreased susceptibility (MIC >8 mg/L) to FZ, with one resistant isolate (MIC = 64 mg/L). VZ and CA inhibited 100% of the isolates at £1 mg/L. VZ was less active against C. glabrata isolates with decreased susceptibility to FZ compared to FZ susceptible isolates. FZ was used in 75% of fungemic patients. CA was the second most commonly used antifungal therapy (11.7% of the patients). In four patients therapy was switched from FZ to CA, two to four days after isolation of the yeast from the blood culture.
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Laboratory of Clinical Bacteriology and Mycology
Hematology Section (-)
Laboratory for Clinical Infectious and Inflammatory Disorders
Faculty of Pharmaceutical Sciences - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.


All items in Lirias are protected by copyright, with all rights reserved.